|
US5997680A
(en)
|
1996-04-30 |
1999-12-07 |
Avery Dennison Corporation |
Method of producing printed media
|
|
EP1100895B1
(de)
*
|
1999-03-15 |
2007-06-13 |
University of British Columbia |
Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
|
|
US6835563B1
(en)
|
1999-06-18 |
2004-12-28 |
Cv Therapeutics |
Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
|
|
JP2003520780A
(ja)
*
|
1999-09-01 |
2003-07-08 |
ユニバーシティ オブ ブリティッシュ コロンビア |
Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
|
|
WO2001032184A2
(en)
*
|
1999-11-01 |
2001-05-10 |
Wisconsin Alumni Research Foundation |
Abc1 modulation for the modulation of cholesterol transport
|
|
US6555323B2
(en)
*
|
2000-02-08 |
2003-04-29 |
Pfizer Inc. |
Assay for ABCA1
|
|
CA2304906A1
(en)
*
|
2000-04-07 |
2001-10-07 |
1411198 Ontario Limited |
13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
|
|
FR2809414B1
(fr)
*
|
2000-05-02 |
2007-08-31 |
Aventis Pharma Sa |
Acide nucleique regulateur du gene abc1, molecules modulant son activite et applications therapeutiques
|
|
FR2815970A1
(fr)
*
|
2000-10-31 |
2002-05-03 |
Aventis Pharma Sa |
Sequences polymorphes du gene humain abca1, leurs utilisations, les methodes et kits de detection
|
|
AU2002210636A1
(en)
*
|
2000-10-31 |
2002-05-15 |
Aventis Pharma S.A. |
Polymorphic sequences of the human ABCA1 gene, their uses, detection methods and kits
|
|
EP1203588A1
(de)
*
|
2000-11-06 |
2002-05-08 |
Bayer Ag |
Sterol-unabhängige Regulierung des ABC1 Promotors mit OncostatinM
|
|
CA2430697A1
(en)
*
|
2000-11-28 |
2002-12-12 |
Amgen, Inc. |
Atp-binding cassette transporter-like molecules and uses thereof
|
|
US20020169137A1
(en)
*
|
2001-02-09 |
2002-11-14 |
Active Pass Pharmaceuticals, Inc. |
Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity
|
|
US7033790B2
(en)
|
2001-04-03 |
2006-04-25 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
WO2002084301A2
(en)
*
|
2001-04-12 |
2002-10-24 |
Xenon Genetics, Inc. |
Screening assay for agents modulating activity of the abca1 protein
|
|
US20050003356A1
(en)
*
|
2001-05-25 |
2005-01-06 |
Hayden Michael R. |
Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
|
|
US20030125338A1
(en)
*
|
2001-06-12 |
2003-07-03 |
Active Pass Pharmaceuticals, Inc. |
Compounds, compositions and methods for modulating beta-amyloid production
|
|
JP2004531268A
(ja)
*
|
2001-06-14 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトトランスポータータンパクおよびそれをコードするポリヌクレオチド
|
|
AU2002317093A1
(en)
*
|
2001-07-03 |
2003-01-21 |
University Of British Columbia |
Screening processes for agents modulating cholesterol levels
|
|
US20030113728A1
(en)
*
|
2001-12-14 |
2003-06-19 |
Jukka Salonen |
Method for assessing the risk of cardiovascular disease
|
|
WO2003057160A2
(en)
*
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
EP1511483A4
(de)
*
|
2002-03-27 |
2009-03-18 |
Smithkline Beecham Corp |
Verfahren zur behandlung mit lxr-modulatoren
|
|
JP2005522222A
(ja)
*
|
2002-04-18 |
2005-07-28 |
エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ａｔｐ結合性カセット遺伝子およびタンパク質の神経変性疾患に関する診断的および治療的使用
|
|
US7226771B2
(en)
|
2002-04-19 |
2007-06-05 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
|
US20050080021A1
(en)
*
|
2002-08-15 |
2005-04-14 |
Joseph Tucker |
Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
|
|
US20040033480A1
(en)
*
|
2002-08-15 |
2004-02-19 |
Wong Norman C.W. |
Use of resveratrol to regulate expression of apolipoprotein A1
|
|
US20050080024A1
(en)
*
|
2002-08-15 |
2005-04-14 |
Joseph Tucker |
Nitric oxide donating derivatives for the treatment of cardiovascular disorders
|
|
FR2847266A1
(fr)
*
|
2002-11-15 |
2004-05-21 |
Genfit S A |
Methodes de criblage de composes modulant le flux de cholesterol et utilisations
|
|
US20050136421A1
(en)
*
|
2003-12-23 |
2005-06-23 |
Hayden Michael R. |
Methods and reagents for modulating cholesterol levels
|
|
EP1566202A1
(de)
*
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Verwendung von resistin-antagonisten zur behandlung von Rheumatoider arthritis
|
|
US7608413B1
(en)
*
|
2005-03-25 |
2009-10-27 |
Celera Corporation |
Kidney disease targets and uses thereof
|
|
RU2464276C2
(ru)
|
2005-05-18 |
2012-10-20 |
Аблинкс Н.В. |
Улучшенные нанотела против фактора некроза опухоли-альфа
|
|
CA2608873C
(en)
|
2005-05-20 |
2017-04-25 |
Ablynx Nv |
Single domain vhh antibodies against von willebrand factor
|
|
AU2006277231A1
(en)
*
|
2005-08-10 |
2007-02-15 |
Takeda Pharmaceutical Company Limited |
Therapeutic agent for diabetes
|
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
|
US8129197B2
(en)
*
|
2006-05-12 |
2012-03-06 |
SOLVO Biotechnológial ZRT. |
Cholesterol loaded insect cell membranes as test proteins
|
|
EP1892530A1
(de)
*
|
2006-08-25 |
2008-02-27 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Bestimmung der Transportaktivität eines Transportproteins
|
|
CA2663001A1
(en)
|
2006-09-21 |
2008-03-27 |
Verenium Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
|
CA2672131C
(en)
|
2006-12-13 |
2016-06-07 |
The Regents Of The University Of California |
Potent and selective mediators of cholesterol efflux
|
|
AU2007336243B2
(en)
|
2006-12-19 |
2012-07-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
EP2115004A2
(de)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
|
|
EP2215125A1
(de)
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Verfahren zur gewinnung von polypeptidkonstrukten mit zwei oder mehreren einzeldomänenantikörpern
|
|
JP2011525476A
(ja)
|
2008-03-05 |
2011-09-22 |
アブリンクス エン．ヴェー． |
新規の抗原結合二量体複合体、その製造方法及び使用
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
US8153606B2
(en)
|
2008-10-03 |
2012-04-10 |
Opko Curna, Llc |
Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
|
|
CN102341498B
(zh)
|
2008-12-04 |
2017-12-19 |
库尔纳公司 |
通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
|
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
|
CA2752237C
(en)
|
2009-02-12 |
2020-03-24 |
Opko Curna, Llc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
EP2403873A1
(de)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
|
|
US20120053229A1
(en)
*
|
2009-03-31 |
2012-03-01 |
The General Hospital Corporation |
Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders
|
|
SG174862A1
(en)
|
2009-04-10 |
2011-11-28 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
CN106237345A
(zh)
|
2009-05-06 |
2016-12-21 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
|
EP2432882B1
(de)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
|
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
|
|
ES2583691T3
(es)
|
2009-06-26 |
2016-09-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
|
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
|
WO2011019815A2
(en)
|
2009-08-11 |
2011-02-17 |
Curna, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
US8791087B2
(en)
|
2009-08-21 |
2014-07-29 |
Curna, Inc. |
Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
|
|
EP2470657B1
(de)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Behandlung von iqgap ('iq-motiv-haltiges gtpase-aktivierendes protein')-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen iqgap
|
|
CA2775111C
(en)
|
2009-09-25 |
2019-12-31 |
Opko Curna, Llc |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
|
UA111708C2
(uk)
|
2009-10-16 |
2016-06-10 |
Бандж Ойлз, Інк. |
Спосіб рафінування олії
|
|
UA109884C2
(uk)
|
2009-10-16 |
2015-10-26 |
|
Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
|
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
|
WO2011082281A2
(en)
|
2009-12-31 |
2011-07-07 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
CA2785832A1
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
|
JP5963680B2
(ja)
|
2010-01-06 |
2016-08-03 |
カッパーアールエヌエー，インコーポレイテッド |
膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
|
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
|
RU2608496C2
(ru)
|
2010-02-22 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
|
|
ES2657969T3
(es)
|
2010-04-02 |
2018-03-07 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
|
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
JP2013525483A
(ja)
|
2010-05-03 |
2013-06-20 |
カッパーアールエヌエー，インコーポレイテッド |
サーチュイン（ｓｉｒｔ）に対する天然アンチセンス転写物の阻害によるサーチュイン（ｓｉｒｔ）関連疾患の治療
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
ES2664572T3
(es)
|
2010-05-26 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1
|
|
CA2799596C
(en)
|
2010-05-26 |
2020-09-22 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
|
HUE054179T2
(hu)
|
2010-06-23 |
2021-08-30 |
Curna Inc |
Nátriumcsatornás, feszültségfüggõ, alfa alegységgel (SCNA) kapcsolatos betegségek kezelése a természetes antiszensz (SCNA)-transzkripció gátlásával
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー，インコーポレイテッド |
Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
|
|
WO2012027601A2
(en)
|
2010-08-25 |
2012-03-01 |
The General Hospital Corporation |
Methods targeting mir-33 micrornas for regulating lipid metabolism
|
|
JP5986998B2
(ja)
|
2010-10-06 |
2016-09-06 |
カッパーアールエヌエー，インコーポレイテッド |
シアリダーゼ４（ｎｅｕ４）への天然アンチセンス転写物の阻害によるｎｅｕ４関連疾患の治療
|
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー，インコーポレイテッド |
α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
|
|
KR101650995B1
(ko)
|
2010-11-08 |
2016-08-25 |
노파르티스 아게 |
Ｃｘｃｒ２ 결합 폴리펩티드
|
|
CA2817256A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー，インコーポレイテッド |
フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
|
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン．ヴェー． |
ＩｇＥに対する免疫グロブリン単一可変ドメイン
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
CN110438125A
(zh)
|
2012-03-15 |
2019-11-12 |
科纳公司 |
通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
US20150191722A1
(en)
*
|
2012-05-16 |
2015-07-09 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating apoa1 and abca1 expression
|
|
CN105050614B
(zh)
|
2013-03-15 |
2019-04-05 |
加利福尼亚大学董事会 |
刺激胆固醇流出的具有降低的毒性的肽
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
CN108473561B
(zh)
|
2015-11-27 |
2022-12-16 |
埃博灵克斯股份有限公司 |
抑制cd40l的多肽
|
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
KR20240076829A
(ko)
|
2016-11-16 |
2024-05-30 |
아블린쓰 엔.브이. |
Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
|
|
TWI811220B
(zh)
|
2017-06-02 |
2023-08-11 |
比利時商艾伯林克斯公司 |
結合聚集蛋白聚糖之免疫球蛋白
|
|
PL3630847T3
(pl)
|
2017-06-02 |
2025-02-03 |
Merck Patent Gmbh |
Immunoglobuliny wiążące adamts
|
|
TWI825021B
(zh)
|
2017-06-02 |
2023-12-11 |
德商麥克專利有限公司 |
與ｍｍｐ１３結合之免疫球蛋白
|
|
KR20250005464A
(ko)
|
2017-06-02 |
2025-01-09 |
메르크 파텐트 게엠베하 |
Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
|
|
CN115433733A
(zh)
|
2021-06-04 |
2022-12-06 |
生物岛实验室 |
环状RNA Circ-ACE2翻译的多肽及其应用
|
|
CN114369162B
(zh)
|
2021-12-28 |
2023-05-30 |
合肥天港免疫药物有限公司 |
抗体及其应用
|
|
CN117402243A
(zh)
|
2022-07-14 |
2024-01-16 |
百奥泰生物制药股份有限公司 |
抗Nectin-4抗体及其应用
|
|
IL318486A
(en)
|
2022-07-27 |
2025-03-01 |
Ablynx Nv |
Polypeptides bind to a specific epitope of the neonatal Fc receptor
|
|
US20240415974A1
(en)
|
2022-12-23 |
2024-12-19 |
Ablynx N.V. |
Protein-based conjugation carriers
|
|
US20240368250A1
(en)
|
2023-02-17 |
2024-11-07 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
US20250034260A1
(en)
|
2023-07-05 |
2025-01-30 |
Sanofi |
Fcrn antagonists for treatment of igg-related diseases and disorders
|
|
WO2025051767A1
(en)
|
2023-09-04 |
2025-03-13 |
Sanofi |
Polypeptides for use in the treatment of glypican-3-expressing tumours
|
|
WO2025056575A1
(en)
|
2023-09-11 |
2025-03-20 |
Novo Nordisk A/S |
Anti il-6 domain antibodies
|